CureGN

摘要 治愈肾小球肾病（CureGN）是一个国家研究所的糖尿病和消化和肾脏疾病 （NIDDK）赞助的多中心国际财团成立于2013年，旨在研究 肾小球疾病（微小病变，局灶节段性肾小球硬化，膜性肾病， 和伊加肾病），了解其潜在的生物学，开发生物标志物来解决疾病 异质性，并最终改善治疗选择。CureGN在以下方面取得了进展：1）建立一个 肾小球疾病患者的大的，种族多样的纵向观察队列; 2）创建丰富的， 精心策划的临床数据集和链接的生物标本; 3）建立最大的数字肾脏储存库 活检;以及4）一个基础设施，将促进核心和辅助的转化和临床研究 研究科学家。 这项补充资金申请是为了测量M型磷脂酶A2受体的血清抗体（抗 PLA 2 R水平）和含血小板反应蛋白I型结构域7A（THSD 7A）的水平。 CureGN膜性肾病受试者。这些生物标志物在临床上并不广泛可用 在CureGN推出时，现已被确定为疾病发病机制、预后 和治疗监测，是任何分析MN的研究的基本信息。CureGN将使用 马约临床生物制药诊断中心实验室，该实验室定期进行这些试验，用于研究和 临床目的。

ABSTRACT Cure Glomerulonephropathy (CureGN) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored, multi-center international consortium established in 2013 to study the natural history of glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy), understand their underlying biology, develop biomarkers to resolve disease heterogeneity, and ultimately improve therapeutic options. CureGN has made progress in: 1) establishing a large, ethnically diverse longitudinal observational cohort of glomerular disease patients; 2) creating a rich, well-curated clinical data set and linked biospecimens; 3) establishing the largest repository of digital kidney biopsies; and 4) an infrastructure that will facilitate translational and clinical research by core and ancillary study scientists. This supplemental funding request is to measure serum antibodies to M-type phospholipase A2 receptor (anti- PLA2R levels) and thrombospondin type I domain-containing 7A (THSD7A) from the existing biosamples of the CureGN membranous nephropathy participants. These biomarkers which were not widely clinically available at the time of CureGN launch have now been identified as key markers for disease pathogenesis, prognosis and therapeutic monitoring and are essential information for any study analyzing MN. CureGN will use the Mayo Clinic BioPharma Diagnostics central laboratory which routinely performs these assays for research and clinical purposes.